Quarterly UpdatesMay 7, 2026, 04:08 PM
Bluejay Diagnostics Q1 Update: SYMON-II Enrollment Nears Completion
AI Summary
Bluejay Diagnostics provided a corporate update for Q1 2026, highlighting significant progress in its Symphony program. The company continued strong enrollment in the SYMON-II pivotal clinical study, reaching approximately 680 out of 750 target patients. Manufacturing readiness for Symphony cartridges advanced with technical issues resolved, and the company is progressing towards regulatory submission. As of March 31, 2026, Bluejay reported $3.7 million in cash and cash equivalents and a net loss of $1.9 million for the quarter.
Key Highlights
- SYMON-II pivotal clinical study enrolled approximately 680 of 750 target patients.
- Successfully resolved technical issues in Symphony cartridge manufacturing process.
- Progressing towards analytical and clinical validation for future 510(k) submission.
- Cash and cash equivalents totaled approximately $3.7 million as of March 31, 2026.
- Reported a net loss of approximately $1.9 million for the first quarter of 2026.